Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by Morningstar users in February 2026. Given February was earnings season, the trends ...

Adding to the mystery, neighbors said police confiscated a white Ford pick-up truck Friday morning belonging to the victim's roommate.

A new family festival is coming to Carlisle this autumn. EdenFest26 will take place on Saturday, September 19, at Carlisle Cricket Club, Edenside, running from 12pm to 8pm. Organisers say the new ...

Asian stocks took some positive cues from Wall Street, which firmed mildly in overnight trade on a mixed recovery in tech. S&P 500 Futures were flat at 22:36 ET (03:36 GMT), with focus turning to a ...

Investing.com-- Australian biopharma firm CSL Ltd (ASX:CSL) said on Wednesday it entered an exclusive licensing agreement with Eli Lilly and Company (NYSE:LLY) granting the latter rights to develop ...

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. CSL and Eli Lilly have struck a strategic ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL booked after-tax impairments of about $1.1 billion, largely related to intellectual property at its Vifor and Seqirus units, reflecting generic competition and lower demand for COVID-related ...

CSL Limited (CSL.AX) reported a significant 81% decline in net profit after tax for the first half of fiscal year 2026 due to one-off costs. The company’s revenue fell 4% to $8.3 billion, while gross ...

The global biotech has lost $36bn in market value and axed its CEO, yet its interim boss insists CSL remains a ‘blue chip’ company. Battling lower vaccination rates in the US under the Trump ...